Who We Are
We are a company operating a CAP accredited, CLIA certified laboratory providing microRNA-based cancer diagnostic services for healthcare providers and their patients.
We are discovering, developing and commercializing next generation diagnostic tests for personalized medicine.
Choose a test to expand
A cutting-edge molecular test that identifies the primary origin in metastatic cancers and cancer of unknown or uncertain primary. This assay identifies 49 cancer origins.Click here for more information
Differentiates primary lung tumors into small cell lung cancer (SCLC), squamous non-small cell lung cancer (NSCLC), non-squamous NSCLC, and CarcinoidClick here for more information
Differentiates the 4 main histological types of primary kidney tumors: namely, benign oncocytoma and the 3 most common subtypes of renal cell carcinoma (RCC): clear cell, papillary and chromophobe
The first single test that accurately differentiates malignant pleural mesothelioma from primary and metastatic carcinomas in the lung and pleuraClick here for more information
Thursday, October 1, 2015 12:28 PM
Rosetta Genomics to Partner with FNApath to Provide Centralized Laboratory Testing Services for Thyroid Cancer
Wednesday, September 30, 2015 9:14 AM
Tuesday, September 22, 2015 12:37 PM